CASP3 and prostate carcinoma: In other primary prostate cancer cells (priCa-2 and priCa-3) and immortalized cell lines (LNCaP and PC-3), treatment with GNE-493 (250 nM) significantly increased the relative caspase-3 activity (Fig. 2G).